Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.89. Ampio Pharmaceuticals shares last traded at $0.88, with a volume of 3,504,478 shares.
Separately, Zacks Investment Research cut Ampio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 9th.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last posted its quarterly earnings data on Friday, July 31st. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bridgeway Capital Management Inc. purchased a new position in shares of Ampio Pharmaceuticals during the second quarter valued at $746,000. Bank of Montreal Can acquired a new position in shares of Ampio Pharmaceuticals in the 2nd quarter valued at about $248,000. Miracle Mile Advisors LLC increased its holdings in shares of Ampio Pharmaceuticals by 100.0% in the 2nd quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 20,000 shares during the period. Chicago Partners Investment Group LLC boosted its holdings in shares of Ampio Pharmaceuticals by 19.4% during the second quarter. Chicago Partners Investment Group LLC now owns 61,523 shares of the specialty pharmaceutical company’s stock worth $72,000 after purchasing an additional 10,000 shares during the period. Finally, Advisor Group Holdings Inc. purchased a new position in Ampio Pharmaceuticals during the first quarter valued at approximately $42,000.
Ampio Pharmaceuticals Company Profile (NYSEAMERICAN:AMPE)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee.
Read More: retirement calculator
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.